Elaine R Miller1, Paige Lewis1, Tom T Shimabukuro1, John Su1, Pedro Moro1, Emily Jane Woo2, Christopher Jankosky2, Maria Cano1. 1. a Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , Georgia , USA. 2. b Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring , Maryland , USA.
Abstract
BACKGROUND: Herpes zoster (HZ), or shingles, is caused by reactivation of varicella-zoster virus in latently infected individuals. Live-attenuated HZ vaccine (zoster vaccine live, ZVL) is approved in the United States for persons aged ≥50 years and recommended by the CDC for persons ≥60 years. METHODS: We analyzed U.S. reports of adverse events (AEs) following ZVL submitted to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system to monitor vaccine safety, for persons vaccinated May 1, 2006, through January 31, 2015. We conducted descriptive analysis, clinical reviews of reports with selected pre-specified conditions, and empirical Bayesian data mining. RESULTS: VAERS received 23,092 reports following ZVL, of which 22,120 (96%) were classified as non-serious. Of reports where age was documented (n = 18,817), 83% were in persons aged ≥60 years. Reporting rates of AEs were 106 and 4.4 per 100,000 ZVL doses distributed for all reports and serious reports, respectively. When ZVL was administered alone among persons aged ≥50 years, injection site erythema (27%), HZ (17%), injection site swelling (17%), and rash (14%) were the most commonly reported symptoms among non-serious reports; HZ (29%), pain (18%), and rash (16%) were the most commonly reported symptoms among serious reports. Six reports included laboratory evidence of vaccine-strain varicella-zoster virus (Oka/Merck strain) infection; AEs included HZ, HZ- or varicella-like illness, and local reaction with vesicles. In our review of reports of death with sufficient information to determine cause (n = 46, median age 75 years), the most common causes were heart disease (n = 28), sepsis (n = 4), and stroke (n = 3). Empirical Bayesian data mining did not detect new or unexpected safety signals. CONCLUSIONS: Findings from our safety review of ZVL are consistent with those from pre-licensure clinical trials and other post-licensure assessments. Transient injection-site reactions, HZ, and rashes were most frequently reported to VAERS following ZVL. Overall, our results are reassuring regarding the safety of ZVL.
BACKGROUND: Herpes zoster (HZ), or shingles, is caused by reactivation of varicella-zoster virus in latently infected individuals. Live-attenuated HZ vaccine (zoster vaccine live, ZVL) is approved in the United States for persons aged ≥50 years and recommended by the CDC for persons ≥60 years. METHODS: We analyzed U.S. reports of adverse events (AEs) following ZVL submitted to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system to monitor vaccine safety, for persons vaccinated May 1, 2006, through January 31, 2015. We conducted descriptive analysis, clinical reviews of reports with selected pre-specified conditions, and empirical Bayesian data mining. RESULTS: VAERS received 23,092 reports following ZVL, of which 22,120 (96%) were classified as non-serious. Of reports where age was documented (n = 18,817), 83% were in persons aged ≥60 years. Reporting rates of AEs were 106 and 4.4 per 100,000 ZVL doses distributed for all reports and serious reports, respectively. When ZVL was administered alone among persons aged ≥50 years, injection site erythema (27%), HZ (17%), injection site swelling (17%), and rash (14%) were the most commonly reported symptoms among non-serious reports; HZ (29%), pain (18%), and rash (16%) were the most commonly reported symptoms among serious reports. Six reports included laboratory evidence of vaccine-strain varicella-zoster virus (Oka/Merck strain) infection; AEs included HZ, HZ- or varicella-like illness, and local reaction with vesicles. In our review of reports of death with sufficient information to determine cause (n = 46, median age 75 years), the most common causes were heart disease (n = 28), sepsis (n = 4), and stroke (n = 3). Empirical Bayesian data mining did not detect new or unexpected safety signals. CONCLUSIONS: Findings from our safety review of ZVL are consistent with those from pre-licensure clinical trials and other post-licensure assessments. Transient injection-site reactions, HZ, and rashes were most frequently reported to VAERS following ZVL. Overall, our results are reassuring regarding the safety of ZVL.
Authors: Jens U Rüggeberg; Michael S Gold; José-Maria Bayas; Michael D Blum; Jan Bonhoeffer; Sheila Friedlander; Glacus de Souza Brito; Ulrich Heininger; Babatunde Imoukhuede; Ali Khamesipour; Michel Erlewyn-Lajeunesse; Susana Martin; Mika Mäkelä; Patricia Nell; Vitali Pool; Nick Simpson Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato Journal: Ann Intern Med Date: 2010-05-04 Impact factor: 25.391
Authors: Paul E Kilgore; Deanna Kruszon-Moran; Jane F Seward; Aisha Jumaan; Frederik P L Van Loon; Bagher Forghani; Geraldine M McQuillan; Melinda Wharton; Laura J Fehrs; Cynthia K Cossen; Stephen C Hadler Journal: J Med Virol Date: 2003 Impact factor: 2.327
Authors: Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: T Craig Cheetham; S Michael Marcy; Hung-Fu Tseng; Lina S Sy; In-Lu Amy Liu; Felicia Bixler; Roger Baxter; James G Donahue; Allison L Naleway; Steven J Jacobsen Journal: Mayo Clin Proc Date: 2015-06-04 Impact factor: 7.616
Authors: Kenneth E Schmader; Ralf Baron; Maija L Haanpää; John Mayer; Alec B O'Connor; Andrew S C Rice; Brett Stacey Journal: Mayo Clin Proc Date: 2010-03 Impact factor: 7.616
Authors: Weina Ke; Enping Hong; Renata F Saito; Maria Cristina Rangel; Jian Wang; Mathias Viard; Melina Richardson; Emil F Khisamutdinov; Martin Panigaj; Nikolay V Dokholyan; Roger Chammas; Marina A Dobrovolskaia; Kirill A Afonin Journal: Nucleic Acids Res Date: 2019-02-20 Impact factor: 16.971
Authors: Anastasia Phillips; Catherine Glover; Alan Leeb; Patrick Cashman; Parveen Fathima; Nigel Crawford; Thomas L Snelling; David Durrheim; Kristine Macartney Journal: BMJ Open Date: 2021-03-25 Impact factor: 2.692
Authors: Elisabeth M Hesse; Tom T Shimabukuro; John R Su; Beth F Hibbs; Kathleen L Dooling; Ravi Goud; Paige Lewis; Carmen S Ng; Maria V Cano Journal: MMWR Morb Mortal Wkly Rep Date: 2019-02-01 Impact factor: 17.586